Skip to main content
Công ty Cổ phần Dược Hậu Giang logo

Công ty Cổ phần Dược Hậu Giang — Investor Relations & Filings

Ticker · DHG ISIN · VN000000DHG0 HSX Manufacturing
Open in API
Filings indexed 182 across all filing types
Latest filing 2022-05-11 Regulatory Filings
Country VN Viet Nam
Listing HSX DHG

About Công ty Cổ phần Dược Hậu Giang

www.dhgpharma.com.vn

Công ty Cổ phần Dược Hậu Giang (DHG Pharma) is a leading pharmaceutical enterprise with over 50 years of experience. The company specializes in the research, development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products, including both supportive and treatment medications. DHG Pharma emphasizes the application of high technology and international production standards to ensure product quality. Key brands include Telfor, Bocalex, Natto DHA, Hapacol, and Biofermin, serving a broad consumer base. Committed to public health, DHG Pharma actively engages in community health initiatives and strives to provide high-quality, accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
DHG: Thông báo thay đổi tổ chức có liên quan của Người nội bộ
Regulatory Filings Classification · 92% confidence The document is a regulatory notification to the stock exchange regarding an insider’s change in related organization. It does not report share transactions (DIRS) nor announce management changes within the company’s board (MANG). It is a compliance/regulatory announcement that does not fit specific categories, so it falls under the fallback category Regulatory Filings (RNS).
2022-05-11 Vietnamese
DHG: HĐQT phê duyệt giao dịch với Taisho trong năm 2022
Regulatory Filings Classification · 65% confidence The document is an extraordinary information disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange regarding board approval of transactions (technology transfer and related contracts) between DHG Pharma and Taisho. It does not contain financial statements, earnings figures, share issuances, M&A proposals, management changes, dividend info, or other specific categories. This is a generic regulatory announcement disclosing a corporate transaction, fitting the fallback category of Regulatory Filings (RNS).
2022-05-11 Vietnamese
DHG: Thông báo thay đổi tổ chức có liên quan của người nội bộ
Regulatory Filings Classification · 90% confidence The document is a disclosure filed to the stock exchange notifying a change in a related organization of an insider (board member) rather than a change in the company’s own board or management, and contains no financial data or report. It is a general regulatory announcement, so it should be classified under Regulatory Filings (RNS).
2022-05-11 Vietnamese
DHG: Báo cáo kết quả giao dịch cổ phiếu của người có liên quan đến người nội bộ Lê Thị Hồng Gấm
Director's Dealing Classification · 90% confidence The document is a formal report filed with the State Securities Commission and the stock exchange detailing the purchase and sale of company shares by an affiliated person of an insider, including names, share counts before and after transactions, transaction values and explanations. This corresponds to insider share transaction reporting. Therefore, it matches the “Director's Dealing” category (insider personal share transactions).
2022-04-29 Vietnamese
DHG: Báo cáo kết quả giao dịch cổ phiếu của Người nội bộ Lê Thị Hồng Nhung
Director's Dealing Classification · 95% confidence The document is a detailed report submitted to the State Securities Commission and stock exchange disclosing the results of share transactions by an internal person (the CFO) of DHG Pharmaceutical. It includes personal details, number of shares held before and after the trade, transaction type, volume, value, and explanation for disclosure. This matches the definition of insider share transactions by directors/executives. Therefore, it should be classified as Director's Dealing (DIRS).
2022-04-27 Vietnamese
DHG: Giải trình KQKD quý 1/2022 so với cùng kỳ năm trước
Earnings Release Classification · 90% confidence The document is an “extraordinary information disclosure” letter to the securities commission and stock exchange providing Q1/2022 business results, with key financial metrics (net sales, profit before/after tax) and growth commentary. It does not include full financial statements or a complete interim report, but rather summarizes and explains quarterly results. This matches an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report. Q1 2022
2022-04-20 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.